MedTrace Logo

Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma

NCT01277653 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2011-01-17

No results posted yet for this study

Summary

There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used

Conditions

Interventions

DEVICE

tumor maker interval shortly

tumor maker interval every 3 month

Sponsors & Collaborators

  • Severance Hospital

    collaborator OTHER

  • Yonsei University

    lead OTHER

Principal Investigators

  • Myoung HA LEE, MD · OFF

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2010-06-30
Completion
2011-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01277653 on ClinicalTrials.gov